Esperion Therapeutics Inc (ESPR) Options

ESPR: Positive Outlook for Esperion Due to Strong Clinical Data and Strategic Expansion

https://markets.businessinsider.com/news/stocks/positive-outlook-for-esperion-due-to-strong-clinical-data-and-strategic-expansion-1034067600

ESPR: Press Release November 26/24

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

https://finance.yahoo.com/news/otsuka-submits-drug-application-japan-130000415.html

and another for 1,167,300 shares at $2.57

https://www.nasdaq.com/market-activity/stocks/espr/after-hours

What is going down? hope not ESPR (lol)

Another large transaction at 16:40

776,606 shares at $2.57

https://www.nasdaq.com/market-activity/stocks/espr/after-hours-trades?page=1&rows_per_page=20

Serious money being thrown around here AH!!

Who knows if it means anything!? ESPR is/has been difficult to call.

Holding well, level II ask loaded again late afternoon.

AH transaction of 1,816,650 shares at $2.57

https://www.nasdaq.com/market-activity/stocks/espr/after-hours-trades

Most definitely

Level II bid firming upside.

https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=ESPR

Next few days will determine if this is truly a trend reversal, imo. ( referring to reversing the up - smack down trend of 2024).

ESPR should hire for investor relations djohnson on st, imo.

All looks good

Accumulation in progress, imo.

Trading here has taken a turn to the positive, imo, ask walls methodically being taken out.

Hope i don't get side smacked for stating that analysis.

Sounds like today's Jefferies conference was a bit more optimistic.

I'm not a member on st but often read that board, many good posters there.

https://www.thelion.com/bin/aio_msg.cgi?cmd=search&symbol=espr

Agreed.

Nice move today with good volume!

Looks like bidding was strong today, that's weird,,,, for ESPR.

Thanks for that information, however that being the case, management failed to use the opportunity to bridge some trust with the investing community by re-confirming a commitment to building shareholder value / working in the best interests of shareholders / pledging to cease share based executive compensation until the company reaches profitability / outline a plan to profitability / detail expense restraint / and outlining a plan to profitability.

I concur that 2024 has been a pivotal year of accomplishment, however the marketplace appears to be skeptical of ESPR mgmt. The current share price and market cap suggests a loss of confidence in ESPR mgmt., imo.

Yup someone is buying trying to keep under wraps

The interview was sponsored by Esperion. That means the interviewer was given a predetermined script written by Esperion, he was not free to ask "top of mind" questions from a shareholder's point of view.

There were no questions about stock performance because Esperion did not want to answer any such questions.

ESPR: On deck for November 19/24

Jefferies London Healthcare Conference

https://www.esperion.com/events/event-details/jefferies-london-healthcare-conference-3

Will it be a re-hash of the poster presentations this past weekend or does Sheldon have something new to lift the spirits of long term shareholders, we will see tomorrow.

Interesting late day trading the last couple of sessions.

I agree never hard questions 

https://www.fiercehealthcare.com/sponsored/2024-pivotal-year-fight-against-cardiovascular-disease

I'm always surprised that the interviewer never asks the respondant about the share price performance. If it been such a pivotal year of accomplishments, why has the stock lost approx. 50% since January 1/24?? Sheldon, can you comment on that and please expand on where you think the market cap should be and/or what exactly is the problem with ESPR stock performance?

ESPR: Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

https://finance.yahoo.com/news/esperion-highlights-exploratory-data-clear-153000058.html


Sellers just can't sell enough, level II ask keeps loading. Level II = hopeless for ESPR, imo.

Esperion Corporate presentation November 2024

https://www.esperion.com/static-files/c900cfb6-ec24-45cf-81a5-ee14d1836a53

Looks like a NDA in Canada during November (slide 11) - no big deal, imo.

The Vanguard Group reported 10,816,762 shares held as of June 30/24.

https://www.nasdaq.com/market-activity/stocks/espr/institutional-holdings

The Vanguard Group reported 13,043,077 shares held as of September 30/24

https://archive.fast-edgar.com/20241104/AB22M222Z222VJD222222ZO2LQ2ST322B262/UnitedStates_13G__EsperionTh.txt

Increase of 2,226,315 shares in the 3rd quarter

Hope so been long almost 4 years

It seems something big is in the works.

Haven't seen Level II act the way it did today, ask in the low 2.50-2.53 were getting repeatedly annihilated.

Could be a major partnering, or a buyout in the works, imo.

Yes one trade almost a million shares 

AH volume on fire!

https://www.nasdaq.com/market-activity/stocks/espr/after-hours

Yup

Strong to the close.

Looking good!, imo.

WOW! nice move north!

Level II bid looking pretty strong.

Pleasantly surprised here this morning!

Nascar promotional collaboration 2024 has failed, imo

https://www.esperion.com/news-releases/news-release-details/rfk-esperion-therapeutics-announce-2024-promotional-schedule

It's time for ESPR mgmt. to get serious and employ competent, dedicated sales reps who know how to get the job done!

https://www.youtube.com/shorts/zlkURHOXkKs

ESPR: Form 10-Q

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001434868/000162828024046307/espr-20240930.htm

ESPR: No funds available to redeem convert.notes, imo.

Cash and cash equivalents $ 144,717,000

and losing 30$ million per quarter - does not look good, imo

ESPR: For what??? Losing money?? ( in bold below)

2024 Financial Outlook

The Company reiterates its full year 2024 operating expense guidance, which is expected to be approximately $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation.

and here under SG&A

The increase is primarily related to the ramp up of our sales force associated with our commercial launch in addition to bonus payments and promotional costs.

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001434868/000162828024045984/espr-20241107.htm

ESPR mgmt. spending appears to be out of control. imo.

Only positive today is that ESPR is not sub$2, imo.

ESPR: Official earnings SEC filing

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001434868/000162828024045984/espr-20241107.htm

Problem areas, imo:

Selling, general and administrative 39,975,000
Interest expense (15,082,000)

Whatever they are spending money on in the "Selling, general and administrative" like NasCar and sales reps - it's not working.

Overall prognosis is poor, and financials are weak.

No news on the converts in the near term will mean no profitability anytime soon, imo.

ESPR:

$2.25 rejected.

Perpetual wall on the ask at $2.25.

What are we anticipating for tomorrow's earnings call?

It seems positive imo, that the earnings release is prior to the open, as opposed to releasing the earnings after the close.

scriptstrend on ST shares some good points.

https://stocktwits.com/scriptstrend2024/message/590178774

ESPR mgmt. needs to pay attention:

https://www.youtube.com/shorts/aZctsTD1iJY

Guess we will see 11/7

I'm not expecting anything spectacular from the 3rd quarter results.

ESPR management team has failed long term investors by squandering shareholder value.
From what i have seen here, their expenditures are not translating into sales.

Great clinical trial results / great product / stock price barely holding a measly $2 dollars says ESPR management has failed - big time, imo.

Just dreaming probably nothing but I'm hoping start of a long march upward 

Is what?

This is it

Esperion to Report Third Quarter 2024 Financial Results on November 7

https://finance.yahoo.com/news/esperion-report-third-quarter-2024-120000845.html

https://finance.yahoo.com/news/millennium-management-llcs-strategic-reduction-230255195.html

As i mentioned previously, there could be something that is repulsive regarding ESPR mgmt.
A fund just doesn't dump that many shares at a bargain price for no reason. Something made then lose interest big time, and the only thing i can think of is ESPR mgmt.

Did this fund take a huge loss upon selling that huge portion of ESPR stock?

Not good, imo.

I agree

I think it would be logical, imo, if ESPR was going to make a move to redeem the convertible notes, to do so on the issue/maturity anniversary date - Nov.15.

If they were to redeem them this year that would be one year prior to the final maturity of November 15/25.

That makes sense, imo, so if they are going to move on the convertible notes this year, we should be hearing about details between now and say November 5/10ish.

ESPR.........................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783

Love it

Another great day here at ESPR!

AH $2.18

Yes thanks still need to make up ground